NAfter the first coronavirus vaccine CVnCoV was frustrated, the Tubingen manufacturer Vacuum cleaner With the emergence of new data on second-generation vaccines, optimism has emerged in the stock market. As the vaccine manufacturer announced on Monday, the candidate vaccine CV2CoV, which is being jointly developed with the British pharmaceutical company GlaxoSmithKline, has shown better immune response and protection in preclinical trials in monkeys.
According to the company, during the investigation, the vaccine also achieved stronger antibody neutralization against selected virus variants. Including incremental versions. The first clinical study with volunteers is expected to begin in the fourth quarter. The share price of Nasdaq, an American technology exchange, rose by about 10% before the market opened, and then still rose slightly.
Decrease in sales and increase in losses
For CureVac, a vaccine manufacturer in which the German government participated last year, this is good news after many setbacks. For example, CureVac’s self-developed mRNA vaccine CVnCoV was only 48% effective a few weeks ago. Competitors BioNTech, Pfizer and Moderna have also developed mRNA vaccines, which are faster and have achieved significantly better protective effects.
——
– (–)
CureVac CEO Franz-Werner Haas confirmed in the release of quarterly data on Monday that his goal is to obtain CVnCoV approval from the European Medicines Agency. “Comprehensive clinical data” is currently being transmitted to the agency.In the 18 to 60 age group vaccine “Shows reliable efficacy characteristics,” he said.
CureVac also announced some changes to the first-generation vaccine clinical development plan. Accordingly, young people aged 12 to 17 should now be included in a separate study, but not in ongoing trials in Peru and Panama. It said that a study with its partner Bayer to check compatibility with seasonal flu vaccination is also being “redesigned.”
In the first half of this year, CureVac reported an operating loss of approximately 264 million euros, mainly due to high research costs, compared to 26 million euros the previous year. Sales fell by 14% to approximately 32 million euros.
